kingpin007
Bluelighter
- Joined
- Aug 24, 2007
- Messages
- 1,888
Warning!!!! MIXING BZP/mCPP and MDMA...
CYP2D6 is the enzyme that breaks down both MDxx and Piperazines. Now when you take the two together they both inhibit the CYP2D6 from breaking down the other. As a consiquence neather realy get broken down and your body can't handle being intoxicated for that long as such. Its thought that taking the mdma first gives the worse results as its the stronger inhibiter.
When you combine all the factors invoved with a good night, drinking, drugs, lots of dancing, sometimes not enough water, etc... you are at a much greater risk of serious harm or possible death through shear exhaustion and over heating.
MDxx =
MDMA
MDA
MDEA
Piperazines =
BZP
TFMPP
cMPP
MDBP
MeOPP
Here are the effects --->
BZP (recreational stimulant)
Users report alertness, euphoria and a general feeling of well being. The perception of certain sensations such as taste, colour or music may be subjectively enhanced. The average duration is longer than that of dextroamphetamine, typically lasting 4-6 hours with reports as long as 8 hours depending on the dose. A recent study has shown that mixtures of BZP with other piperazine drugs such as TFMPP share certain pharmacodynamic traits with MDMA
TFMPP (hallucinogen)
BZP and TFMPP has been associated with a range of side effects, including insomnia, anxiety, nausea and vomiting, headaches and muscle aches which may resemble migraine, seizures, impotence, and rarely psychosis, as well as a prolonged and unpleasant hangover effect similar to that produced by alcohol. These side effects tend to be significantly worsened when the BZP/TFMPP mix is consumed alongside alcohol, especially the headache, nausea and hangover.
However it is difficult to say how many of these side effects are produced by TFMPP itself, as it has rarely been marketed without BZP also being present, and all of the side effects mentioned are also produced by BZP (which has been sold as a single drug). Studies into other related piperazine drugs such as mCPP suggest that certain side effects such as anxiety, headache and nausea are common to all drugs of this class, and pills containing TFMPP are reported by users to produce comparatively more severe hangover effects than those containing only BZP.
pFPP (hallucinogen)
has little stimulant effects. Its effects have been described as similar to a cross between Fluoxetine and a very small dose of LSD. higher doses cause a range of side effects including migraine headaches, muscle aches, anxiety, nausea and vomiting.
For a more scientific explanation -->
Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis.
Department of Experimental and Clinical Toxicology, Institute of Experimental and Clinical Pharmacology and Toxicology, University of Saarland, D-66421 Homburg (Saar), Germany. [email protected]
Designer drugs of the amphetamine type (eg, MDMA, MDEA, MDA), of the new benzyl or phenyl piperazine type (eg, BZP, MDBP, mCPP, TFMPP, MeOPP), or of the pyrrolidinophenone type (eg, PPP, MOPPP, MDPPP, MPPP, MPHP) have gained popularity and notoriety as rave drugs. These drugs produce feelings of euphoria and energy and a desire to socialize. Although in the corresponding drug scene designer drugs have the reputation of being safe, studies in rats and primates in combination with human epidemiologic investigations indicate potential risks to humans. Thus, a variety of adverse effects have been associated with the use/abuse of this class of drugs in humans, including a life-threatening serotonin syndrome, hepatotoxicity, neurotoxicity, and psychopathology. Metabolites were suspected to contribute to some of the toxic effects. Therefore, knowledge of the metabolism is a prerequisite for toxicologic risk assessment. The metabolic pathways, the involvement of cytochrome P450 isoenzymes in the main pathways, and their roles in hepatic clearance are described for designer drugs of different groups. In summary, polymorphically expressed CYP2D6 was the major enzyme catalyzing the major metabolic steps of the studied piperazine- and pyrrolidinophenone-derived designer drugs. However, it cannot be concluded at the moment whether this genetic polymorphism is of clinical relevance.
http://www.ncbi.nlm.nih.gov/sites/en...m=BZP CYP2D6
CYP2D6 is the enzyme that breaks down both MDxx and Piperazines. Now when you take the two together they both inhibit the CYP2D6 from breaking down the other. As a consiquence neather realy get broken down and your body can't handle being intoxicated for that long as such. Its thought that taking the mdma first gives the worse results as its the stronger inhibiter.
When you combine all the factors invoved with a good night, drinking, drugs, lots of dancing, sometimes not enough water, etc... you are at a much greater risk of serious harm or possible death through shear exhaustion and over heating.
MDxx =
MDMA
MDA
MDEA
Piperazines =
BZP
TFMPP
cMPP
MDBP
MeOPP
Here are the effects --->
BZP (recreational stimulant)
Users report alertness, euphoria and a general feeling of well being. The perception of certain sensations such as taste, colour or music may be subjectively enhanced. The average duration is longer than that of dextroamphetamine, typically lasting 4-6 hours with reports as long as 8 hours depending on the dose. A recent study has shown that mixtures of BZP with other piperazine drugs such as TFMPP share certain pharmacodynamic traits with MDMA
TFMPP (hallucinogen)
BZP and TFMPP has been associated with a range of side effects, including insomnia, anxiety, nausea and vomiting, headaches and muscle aches which may resemble migraine, seizures, impotence, and rarely psychosis, as well as a prolonged and unpleasant hangover effect similar to that produced by alcohol. These side effects tend to be significantly worsened when the BZP/TFMPP mix is consumed alongside alcohol, especially the headache, nausea and hangover.
However it is difficult to say how many of these side effects are produced by TFMPP itself, as it has rarely been marketed without BZP also being present, and all of the side effects mentioned are also produced by BZP (which has been sold as a single drug). Studies into other related piperazine drugs such as mCPP suggest that certain side effects such as anxiety, headache and nausea are common to all drugs of this class, and pills containing TFMPP are reported by users to produce comparatively more severe hangover effects than those containing only BZP.
pFPP (hallucinogen)
has little stimulant effects. Its effects have been described as similar to a cross between Fluoxetine and a very small dose of LSD. higher doses cause a range of side effects including migraine headaches, muscle aches, anxiety, nausea and vomiting.
For a more scientific explanation -->
Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis.
Department of Experimental and Clinical Toxicology, Institute of Experimental and Clinical Pharmacology and Toxicology, University of Saarland, D-66421 Homburg (Saar), Germany. [email protected]
Designer drugs of the amphetamine type (eg, MDMA, MDEA, MDA), of the new benzyl or phenyl piperazine type (eg, BZP, MDBP, mCPP, TFMPP, MeOPP), or of the pyrrolidinophenone type (eg, PPP, MOPPP, MDPPP, MPPP, MPHP) have gained popularity and notoriety as rave drugs. These drugs produce feelings of euphoria and energy and a desire to socialize. Although in the corresponding drug scene designer drugs have the reputation of being safe, studies in rats and primates in combination with human epidemiologic investigations indicate potential risks to humans. Thus, a variety of adverse effects have been associated with the use/abuse of this class of drugs in humans, including a life-threatening serotonin syndrome, hepatotoxicity, neurotoxicity, and psychopathology. Metabolites were suspected to contribute to some of the toxic effects. Therefore, knowledge of the metabolism is a prerequisite for toxicologic risk assessment. The metabolic pathways, the involvement of cytochrome P450 isoenzymes in the main pathways, and their roles in hepatic clearance are described for designer drugs of different groups. In summary, polymorphically expressed CYP2D6 was the major enzyme catalyzing the major metabolic steps of the studied piperazine- and pyrrolidinophenone-derived designer drugs. However, it cannot be concluded at the moment whether this genetic polymorphism is of clinical relevance.
http://www.ncbi.nlm.nih.gov/sites/en...m=BZP CYP2D6
Last edited:
